FIA
CARM

FNY Investment Advisers’s Carisma Therapeutics CARM Stock Holding History

FNY Investment Advisers’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-1,250
Closed -$37K – 908
2019
Q2 		$37K Buy
+1,250
New +$37.4K 0.01% 403

Other funds holding CARM

KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
TG
TRV GP Boston, Massachusetts $18.9M AUM 541.67% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
HP
Hikari Power Tokyo, Japan $1.15B AUM 5.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

FNY Investment Advisers's CARM Position: Q3 2019 in Review

FNY Investment Advisers sold out of Carisma Therapeutics (CARM) in Q3 2019, closing a stake of 1,250 shares — an estimated $37K sold.

FNY Investment Advisers first reported a position in CARM in Q2 2019 and held it in 1 quarter. The position peaked at $37K in Q2 2019. 37 funds tracked by Wall St. Rank hold CARM as of Q3 2019.

  • FNY Investment Advisers reported no remaining Carisma Therapeutics position as of Q3 2019 after selling out during the quarter.
  • FNY Investment Advisers sold 1,250 Carisma Therapeutics shares in Q3 2019, an estimated $37K.
  • FNY Investment Advisers first reported a position in Carisma Therapeutics in Q2 2019 and held it in 1 quarter.
  • FNY Investment Advisers's Carisma Therapeutics position peaked at $37K in Q2 2019.
  • 37 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q3 2019.

Based on FNY Investment Advisers's 13F filing for Q3 2019, filed 25 Oct 2019.